Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Decrease in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 11,313 shares, a decline of 41.4% from the July 15th total of 19,290 shares. Based on an average daily volume of 16,846 shares, the short-interest ratio is currently 0.7 days. Approximately 0.5% of the company’s shares are short sold.

Xenetic Biosciences Stock Performance

Shares of NASDAQ:XBIO opened at $3.28 on Monday. The stock has a market capitalization of $7.51 million, a P/E ratio of -2.83 and a beta of 2.10. Xenetic Biosciences has a 1-year low of $1.90 and a 1-year high of $13.93. The business has a 50-day moving average price of $2.88 and a two-hundred day moving average price of $2.84.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. The business had revenue of $0.66 million during the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Xenetic Biosciences has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC acquired a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.